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Abstract: This article reviews and updates published data on cefditoren in the evolving   scenario 
of resistance among the most prevalent isolates from respiratory tract infections in the community 
(Streptococcus pyogenes, Haemophilus influenzae, and Streptococcus pneumoniae). By relating 
the in vitro activity of cefditoren (in national and multinational surveillance and against isolates 
with emerging resistant genotypes/phenotypes) to its pharmacokinetics, the cefditoren pharma-
codynamic activity predicting efficacy (in humans, animal models, and in vitro simulations) is 
analyzed prior to reviewing clinical studies (tonsillopharyngitis, sinusitis, acute exacerbations 
of chronic bronchitis, and community-acquired pneumonia) and the relationship between 
bacterial eradication and clinical efficacy. The high in vitro activity of cefditoren against the most 
prevalent respiratory isolates in the community, together with its pharmacokinetics (enabling a 
twice daily regimen) leading to adequate pharmacodynamic indexes covering all S. pyogenes, 
H. influenzae, and at least 95% S. pneumoniae isolates, makes cefditoren an antibiotic that will 
play a significant role in the treatment of respiratory tract infections in the community. In the 
clinical setting, studies carried out with cefditoren showed that treatments with the 400 mg 
twice daily regimen were associated with high rates of bacteriological response, even against 
penicillin-nonsusceptible S. pneumoniae, with good correlation between bacteriological efficacy/
response and clinical outcome.
Keywords: cefditoren, Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneu-
moniae, community-acquired respiratory tract infections
Scenario for new antibiotics for the treatment  
of respiratory tract infections
Infections, mainly respiratory tract infections,1 are the most frequent reason for seeking 
medical attendance in the community.2 Around 85% to 90% of global antibiotic con-
sumption occurs in the community, with 80% of this consumption for the treatment 
of respiratory tract infections.3 Streptococcus pyogenes causing pharyngotonsillitis, 
and Streptococcus pneumoniae and Haemophilus influenzae causing otitis and lower 
respiratory tract infections (acute exacerbations of chronic bronchitis and community-
acquired pneumonia), are the most prevalent isolates in community-acquired respi-
ratory tract infections, and can be considered index bacteria for assessing antibiotic 
resistance.
Several studies carried out in Spain have shown that antibiotic consumption is the 
main reason for resistance selection in the community.4 These studies related consump-
tion of β-lactams (mainly second-generation oral cephalosporins) and macrolides (mainly 
long half-life macrolides) with penicillin/erythromycin resistance in S.   pneumoniae Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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(with temporal5 and geographical6 associations) and with 
ampicillin/amoxicillin resistance in H. influenzae (this study 
showed higher accountability for aminopenicillins with or 
without clavulanic acid).7 Other studies showed that macrolide 
consumption (mainly long half-life macrolides) was linked 
to erythromycin resistance in S. pyogenes.8,9
The Spanish data show that the analysis of resistance in 
the community should be seen as a global problem, since 
geographical and temporal relationships between resistance 
in these target bacteria have been described, leading to the 
concepts of co-resistance selection and co-selection of 
resistance. Due to co-resistance selection, there is a signifi-
cant association between penicillin and erythromycin resis-
tance in S. pneumoniae,10,11 and because of the co-selection 
of resistance, the penicillin/erythromycin resistance in 
S. pneumoniae is associated with ampicillin resistance in 
H. influenzae.10 Further, this resistance in S. pneumoniae 
and in H. influenzae is significantly related to erythromycin 
resistance in S. pyogenes from a geographical perspective.10 
The geographical relationship between macrolide resistance 
in S. pneumoniae and in S. pyogenes in Spain emphasizes the 
idea of resistance as a global problem, since S. pneumoniae 
is isolated mainly from adults, from lower respiratory tract 
samples, with MLSB as the prevalent resistance phenotype, 
while S. pyogenes is isolated mainly from children, from 
pharyngotonsillitis, with M-efflux as the prevalent resistance 
phenotype.10,11
The need for new antibiotics is defined mainly by their 
antimicrobial activity against the prevalent resistance pheno-
types, rather than the activity against phenotypes susceptible 
to antibiotics previously used in the community. The analysis 
of resistance prevalence and phenotypes reported in index 
bacteria will define the context in which new antibiotics 
should demonstrate in vitro activity.
S. pyogenes
S. pyogenes is highly susceptible to penicillin (strains with 
minimum inhibitory concentration [MIC] .0.12 µg/mL have 
not been found) and should be considered susceptible to all 
β-lactams. In contrast, resistance to erythromycin is widely 
reported, with geographical variations in prevalence rates and 
predominant resistance phenotypes. The rate of erythromycin 
resistance in S. pyogenes varies among countries, from 6.9% 
in the US (56% MLSB phenotype)12 to 25.6% in Hong Kong.13 
In a recent study performed in Eastern Europe, the rate of 
erythromycin resistance in S. pyogenes was low (,10%) in 
Romania and Baltic countries, intermediate (10%–20%) in 
Poland and the Czech Republic, and high (.25%) in Hungary 
and Slovakia.14 The predominant (75%) resistance   phenotype 
was MLSB (58.9% of the constitutive phenotype plus 16.1% 
of the inducible phenotype).14 In Spain, although the rates 
of erythromycin resistance have decreased in SAUCE 
(Susceptibility to the Antimicrobials Used in the Community 
in España) studies over recent years (26.7% in 1996–1997, 
20.4% in 1998–1999, 24.3% in 2001–2002, and 19.0% in 
2006–2007), no temporal decreasing trend for erythromycin 
resistance was found in contrast to an increasing trend in the 
percentage of the MLSB phenotype (7.0%, 10.5%, 14.0%, 
and 35.5%, respectively, among resistant strains in the cor-
responding SAUCE studies).15
Since both mechanisms of resistance (M-efflux and 
MLSB) imply resistance to 14- and 15-membered macrolides, 
erythromycin resistance implies resistance to azithromycin 
and clarithromycin.16
H. influenzae
Resistance to β-lactams in H. influenzae is defined using 
ampicillin as a marker of resistance. Most ampicillin-resistant 
isolates are β-lactamase producers: TEM-1, TEM-2 and, with 
lower frequency, ROB-1. The remaining ampicillin-resistant 
isolates are resistant due to mutations in the ftsI gene causing 
alterations in the amino acid sequences of penicillin-binding 
protein 3 (PBP3). Resistance phenotypes showing mutations 
in the ftsI gene are BLNAR (β-lactamase negative ampicillin 
resistant) and BLPACR (β-lactamase positive amoxicillin/
clavulanic acid resistant), which exhibits both resistance 
mechanisms (β-lactamase production and mutations in the 
ftsI gene). These phenotypes should be considered also 
resistant to amoxicillin/clavulanic acid, ampicillin/sulbactam, 
piperacillin/tazobactam, cefaclor, and cefuroxime.17
The epidemiology of ampicillin resistance varies geo-
graphically and temporally. In a global surveillance including 
15 countries (in 2003–2004), ampicillin resistance ranged 
from 8.7% in South Africa to 29.6% in Asia.18 In the US, 
ampicillin resistance averaged about 30% in the period 
2001–2005.19 In a European surveillance (2004–2005) 
including isolates from 11 countries, mean ampicillin resis-
tance was 16.4%, resistance due to β-lactamase produc-
tion ranging from 17.6% in France to 0% in Germany and 
Netherlands, and BLNAR isolates ranging from 33.9% in 
Spain to 0% in France and Netherlands.20 In Spain (SAUCE 
studies: 1996–1997, 1998–1999, 2001–2002, 2006–2007) 
ampicillin resistance seems to be decreasing over time 
(38.6%, 30.0%, 25.1%, and 16.1%, respectively), both resis-
tance due to β-lactamase production (25.7%, 23.0%, 20.0%, 
and 15.7%, respectively) and to the BLNAR phenotype Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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(13.5%, 12.0%, 4.4%, and 0.7%, respectively).15 However the 
rate of BLNAR and BLPACR among strains exhibiting high 
MIC of ampicillin ($1 µg/mL) or amoxicillin/clavulanic acid 
($2/1 µg/mL) is higher, as shown in a Spanish multicenter 
study carried out in 2005–2007 where among the 196 strains 
with high MICs identified, 165 showed mutations in the ftsI 
gene (73% BLNAR and 27% BLPACR).21 The situation in 
Japan is the most worrisome since in nationwide global sur-
veillances the percentage of BLNAR and BLPACR strains 
was 29.1% and 6.7%, respectively, in adults in 200722 and 
59.3% and 6.4%, respectively, in children in 2004.23
According to the SAUCE study in 2006–2007, similar 
susceptibility rates to ampicillin or amoxicillin/clavulanic 
acid were obtained by applying CLSI (Clinical and Labora-
tory Standards Institute) and PK/PD breakpoints (pharma-
codynamic [PD] breakpoints predicting eradication that are 
obtained through the relationship between pharmacokinetic 
[PK] parameters and MIC).15 In contrast, rates of suscepti-
bility to cefaclor changed from 97.8% (by applying CLSI 
breakpoints) to 25.8% (PK/PD breakpoints).15 Similarly, 
percentages of susceptibility to macrolides were high by 
applying CLSI breakpoints (99.3% and 100% to clarithro-
mycin and azithromycin, respectively) but sharply decreased 
to 5.1% and 23.8%, respectively, when PK/PD breakpoints 
were considered,15 probably due to the presence of efflux 
pumps in virtually all H. influenzae strains. This suggests that 
current CLSI breakpoints for H. influenzae for macrolides 
should be reviewed.24
S. pneumoniae
Except for fluoroquinolones (worldwide nonsusceptibility 
rates to levofloxacin are as low as ,2.5%25), antibiotic 
resistance in S. pneumoniae also depends on geographic 
location and time, antibiotic pressure (consumption) and the 
introduction of the 7-valent conjugate vaccine (PCV7 includ-
ing serotypes most associated with penicillin/erythromycin 
nonsusceptibility) being the principal influencing factors. In 
a worldwide surveillance study, penicillin nonsusceptibility 
was 66% in South Africa, 47.3% in Asia-Pacific, 44.1% in 
the Middle East, 42.1% in North America, 37.9% in Latin 
America, and 27.9% in Europe.26 Penicillin (with CLSI-
defined breakpoints for oral penicillin) is the best epidemio-
logical marker since nonsusceptibility rates to β-lactams and 
to macrolides are clustered in penicillin-intermediate and/or 
in penicillin-resistant S. pneumoniae.27 In this sense, in a 
2001–2002 surveillance study (mainly including noninva-
sive isolates) in Spain the reported nonsusceptibility rates 
to β-lactams and macrolides were around 0% and 15%, 
respectively, among penicillin-susceptible strains, around 
80% for cefaclor, 50% for cefuroxime axetil, and 60% for 
macrolides among penicillin-intermediate strains, and around 
35% for amoxicillin/clavulanic acid, 100% for cefaclor 
and cefuroxime axetil, 15% for cefotaxime, and 60% for 
macrolides among penicillin-resistant strains.27
Focusing on invasive isolates, the increase in the preva-
lence of certain serotypes and of penicillin nonsusceptibility, 
which was reported in the 1980s and 1990s in relation to 
antibiotic consumption, reversed in the 2000s when PCV7 was 
introduced for immunization of children.28,29 The introduction 
of PCV7 has not only dramatically reduced the incidence of 
invasive pneumococcal disease but also markedly decreased 
PCV7 serotypes, thus affecting the rate of penicillin and eryth-
romycin nonsusceptibility in invasive isolates both from chil-
dren and adults.29,30 The SAUCE studies in Spain (1996–1997, 
1998–1999, 2001–2002, 2006–2007) have shown a decreasing 
trend for penicillin nonsusceptibility rates (60.0%, 50.2%, 
43.9%, and 22.9%, respectively) in contrast to erythromycin 
nonsusceptibility, which has shown lower variations (36.5%, 
34.9%, 34.5%, and 22.9%, respectively), the MLSB resistance 
phenotype decreasing over time (from 98.4% in 1996–1997 
to 81.3% in 2006–2007). Of all invasive isolates received in 
the Spanish Reference Laboratory for Pneumococci in 2009, 
85.3% belonged to serotypes not included in PCV7, around 
20% being nonsusceptible to penicillin (≈50% of them sero-
type 19A).31 Although serotypes 1 and 19A showed significant 
increasing trends, only serotype 19A was linked to   penicillin 
nonsusceptibility.31–33 In this sense, in parallel to the increasing 
trend for serotype 19A28,32 there was an increasing trend for 
penicillin nonsusceptibility in serotype 19A28 which reached 
around 80% in 2008 and was associated with amoxicillin and 
cefotaxime nonsusceptibility in around 20% of isolates.32
The emergence of amoxicillin resistance in pre-existing 
penicillin-resistant clones has been reported among PCV7 
and non-PCV7 serotypes,34,35 with troublesome clones 
(Spain23F-1, Spain9V-3, Spain6B-2 and Spain14-5) exhibit-
ing MIC values of amoxicillin higher than of penicillin.34 
In addition, in 2008 a published article described in 9 Roma-
nian isolates of the sequence type ST321 (or the nearest 
matched type with only a single or double locus variance), 
belonging to serotypes 23F or 19A, the presence of a new 
cluster in regions 595–600 of PBP2X together with a new 
murM allele (with absence of mutations in the conserved 
domain of PBP1A).35 These isolates showed MICs of 
penicillin, amoxicillin, and cefotaxime of $16 µg/mL,35,36 
representing a breakthrough increase in the magnitude of 
resistance to β-lactams.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
88
Soriano et al
Also of great concern is the existence of isolates showing 
multiple resistance defined as full resistance to 2 or more 
of the 6 classes of antibacterials represented by penicillin, 
erythromycin, cefuroxime, tetracyclines, trimethoprim/
sulfamethoxazole, and levofloxacin. Multiple resistance in 
S. pneumoniae has been reported at rates as high as 19.1% 
in North America, 27.7% in Western Europe, and 80.4% in 
the Far East.25
According to the SAUCE study in 2006–2007, no differ-
ences in susceptibility rates were found by applying PK/PD and 
CLSI breakpoints, with susceptibility rates to macrolides 
of ≈80%, to amoxicillin/clavulanic acid of ≈95%, to 
cefuroxime axetil of ≈95%, and to cefotaxime of ≈100%.15
Cefditoren: in vitro activity, 
pharmacokinetics, and 
pharmacodynamics
Cefditoren is the active form of cefditoren pivoxil, an oral 
third-generation aminothiazolyl cephalosporin with structural 
components similar to those of first- and third-generation 
cephalosporins.37 In cefditoren, the group attached at the 
C-7 position of the cephem skeleton affords activity against 
Gram-negative microorganisms, whereas the one attached 
at the C-3 position (not seen in other nonfirst-generation 
cephalosporins) affords activity against Gram-positive 
bacteria.37 According to the study by Yamada et al on the 
structure of the PBP2X of S. pneumoniae complexed with 
cefditoren, the unique methylthiazole group of the C-3 side 
chain of the cephem skeleton fits well into the PBP binding 
pocket, a feature that is likely to play a role in the high activity 
of cefditoren against S. pneumoniae.38
In vitro activity
Cefditoren exhibited high intrinsic activity against S. pyogenes, 
with MIC50/MIC90 values of #0.03/#0.03 µg/mL, both against 
macrolide-susceptible or -resistant strains, in a multicenter, 
multinational study performed in Europe.14 The intrinsic activ-
ity of cefditoren was similar against H. influenzae (MIC50/
MIC90 = #0.03/#0.03 µg/mL), as shown in a study carried out 
in 8 Central and Eastern European countries in 2005–2006.39 
This in vitro activity against H. influenzae was not influenced 
by the phenotype/genotype of the isolates, with similar 
intrinsic activity to cefotaxime against ampicillin-susceptible,   
beta-lactamase positive, BLNAR, and BLPACR strains (MIC90 
values ranging from #0.015 to 0.06 µg/mL).21,40
For S. pneumoniae the multicenter, multinational 
ARISE study carried out in Europe in the pre-PCV7 era 
(thus including a large number of isolates from serotypes 
6, 9, 14, and 23, traditionally linked to resistance) showed 
MIC50/MIC90 values of cefditoren of #0.03/0.5 µg/mL.41 
After PCV7 introduction the prevalence of vaccine sero-
types greatly decreased (together with a decrease in penicil-
lin nonsusceptibility),28,29 and in the most recent SAUCE 
study (2006–2007) MIC50/MIC90 values of cefditoren 
were #0.015/0.125 µg/mL.15 In parallel there has been a 
high increase in the prevalence of non-PCV7 serotypes28,29 
which occupied the niche left by PCV7 serotypes, leading to 
a prevalence of 85.3% of non-PCV7 serotypes isolates among 
invasive isolates in 2009 in Spain.31 Of these, 80% were 
susceptible to penicillin (MIC90 of cefditoren #0.06 µg/mL) 
and 20% were nonsusceptible (of these, 56.3% for serotype 
19A, 9.8% for serotype 24F, 7.0% for serotype 35B, 5.4% 
for serotype 6A, and 4.4% for serotypes 11A, 15A, and 23B 
each).31 The intrinsic activity of cefditoren against these 
penicillin nonsusceptible non-PCV7 serotypes varied on 
serotype basis: MIC90 of 1 µg/mL for penicillin-resistant and 
0.5 µg/mL for penicillin-intermediate serotype 19A isolates, 
0.5 µg/mL for serotype 11A, 0.25 µg/mL for serotypes 35B, 
6A, and 15A, 0.12 µg/mL for serotype 24F and 0.06 µg/mL 
for serotype 23B isolates.31
The intrinsic activity of cefditoren was markedly higher 
than that of other β-lactams against isolates with resistance 
patterns highly troubling as strains belonging to clones 
Spain23F-1, Spain9V-3, Spain6B-2, and Spain14-5. Against these 
strains cefditoren showed MIC90 values #1 µg/mL, 1 dilution 
lower than values for cefotaxime.34 The intrinsic activity of 
cefditoren against the exceptional strains of sequence type 
ST321 (serotypes 23F or 19A) with a new cluster in regions 
595–600 of PBP2X and a new murM allele warrants special 
attention.35 These isolates, representing the isolates most 
resistant to β-lactams described in the literature, were inhib-
ited by 2 µg/mL of cefditoren in contrast to MICs $ 16 µg/mL 
of penicillin, amoxicillin, and cefotaxime.35
No inoculum effect was observed with cefditoren when test-
ing several clinical isolates of S. pneumoniae and H.   influenzae 
by determining its in vitro activity using inoculum sizes of 104 
to 105 colony forming units (cfu)/mL compared with the one 
obtained with inocula of 107 to 108 cfu/mL.42
Pharmacokinetics
When orally administered to humans the prodrug cefditoren 
pivoxil is completely and rapidly hydrolyzed to cefditoren, 
the bioavailability being low in the fasting state (15%–20%). 
However when administered after high fat meals the bioavail-
ability of cefditoren increases, Cmax and AUC values being 
50% and 70%, respectively, higher than those   determined Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
89
Cefditoren and respiratory tract infections
in the fasting state.37 In a phase I study in Caucasians 
  administed 400 mg cefditoren pivoxil single dose in the fed 
state, Cmax was 3.7 ± 0.7 µg/mL, Tmax was 2 hours, AUC∞ was 
12.5 ± 1.6 µg × h/mL, and t1/2 was 1.54 ± 0.20 hours.43
Pharmacodynamics
By relating pharmacokinetic variables and susceptibility data 
(ie, antibiotic drug exposure relative to in vitro MIC), PK/
PD breakpoints indicate the highest MIC that produces the 
adequate value for the relevant PK/PD parameter predicting 
bacterial killing, eradication, and clinical outcome. In the case 
of cefditoren, pharmacodynamics in relation to community-
acquired respiratory tract infections should be studied espe-
cially for S. pneumoniae, since H. influenzae and S. pyogenes 
are uniformly and highly susceptible to cefditoren. For cefdi-
toren, as for β-lactams, the time (t) (expressed as percentage 
of the dosing interval) that antibiotic concentrations exceed 
the value of MIC (t . MIC) is the index predicting efficacy 
with a cut-off value of 40% for clinical cure in humans,44,45 
although a t . MIC of 33% has been used as bacteriostatic 
endpoint and susceptibility is defined by the FDA and CLSI 
as inhibition by usually achievable concentrations of the 
recommended dose.17,46
Data from a phase I study in Caucasians showed that 
the 400 mg twice daily regimen of cefditoren pivoxil gave 
a value of t . MIC for total drug of about 55% for MIC of 
0.5 µg/mL, 68% for MIC of 0.25 µg/mL, 81% for MIC of 
0.12 µg/mL, and 94% for MIC of 0.06 µg/mL.43 Classically 
the unbound fraction of an antimicrobial has been consid-
ered the active fraction in vitro; however the reversibility 
of protein binding implies that limitation of activity may be 
far from absolute, even in highly protein bound agents.47 For 
cefditoren, which exhibits 88% protein binding,37 this could 
be postulated as a limitation to its in vivo intrinsic activity. 
Considering that protein binding rates in humans and mice 
are equal for cefditoren, the extrapolation to humans of 
pharmacodynamic data obtained in animal models acquires 
special interest. A pneumococcal sepsis model in mice 
infected by strains with exceptionally high cefditoren MIC 
(1–2 µg/mL) showed that cefditoren t . MIC of ≈35% (free 
t . MIC of ≈20%) produced 100% survival in contrast to 
placebo (0% survival).48 Free t . MIC of ≈20% was also 
related to .99.9% reduction in bacterial load (of 2   isolates 
serotypes 6B and 15A with MIC = 0.25 µg/mL) in an 
in vitro pharmacodynamic simulation with physiological 
albumin concentrations and 86% protein binding rate in the 
device.49 In a cefditoren Monte Carlo simulation (using data 
determined in the phase I study43) considering 33% t . MIC 
(bacteriostatic endpoint) as endpoint value (approximately 
the value obtained in the mice model for total drug), strains 
with MICs up to 0.5 µg/mL were covered by cefditoren.46 
When applying free drug 33% t . MIC (a value higher than 
the one required in the mice model for 100% survival and 
in the pharmacodynamic simulation for .99.9% reduction 
in bacterial load), strains up to 0.25 µg/mL were covered.46 
If the classical theoretical value of free t . MIC of 40% 
was considered, strains up to 0.12 µg/mL were covered by 
cefditoren in the Monte Carlo simulation.46
According to these data, the cefditoren breakpoint for 
nonsusceptibility should be within the range #0.12 µg/mL 
and #0.5 µg/mL. This latter value has been proposed 
by several authors considering cefditoren MIC90 values 
lower than the breakpoints values for parenteral third-
generation cephalosporins and the pharmacokinetics of 
cefditoren,50–52 and was the breakpoint approved by the 
Spanish Agency during the registration procedure in Europe 
(  susceptibility #0.5 µg/mL).53 The most conservative break-
point (#0.12 µg/mL) has been proposed by the FDA.54 With 
this breakpoint, 94.9% of S. pneumoniae isolates in Spain in 
2006–2007 are covered.15
An interesting pharmacodynamic result for cefditoren 
in the above-mentioned mice model was the decrease in the 
required t . MIC values producing efficacy when animals 
were passively immunized (with nonprotective levels of 
specific antibodies) prior to infection. The required values 
of t . MIC linked to efficacy decreased from ≈35% (free 
t . MIC of ≈20%) in nonimmunized animals to ≈25% (free 
t . MIC of ≈15%) in the immunized ones.48 This is interest-
ing in the context where specific antibodies (at nonprotective 
levels) are likely to be present before S. pneumoniae infection, 
since colonization is to some extent a B-cell immunizing 
event55,56 and preventive measures such as pneumococcal 
vaccination are increasingly been used in the community. The 
benefit of these findings would not be the decrease of admin-
istered doses, but rather the coverage by current regimens of 
the exceptional strains with high MIC values.
Cefditoren has shown a postantibiotic effect greater than 
1 hour for S. pneumoniae and S. pyogenes, which also sup-
ports the twice daily regimen for the treatment of respiratory 
tract infections.57
Efficacy clinical studies with 
cefditoren in the treatment of 
upper respiratory tract infections
During the clinical development of cefditoren, 3 compara-
tive multicenter studies were performed with cefditoren Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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and penicillin V as comparator in pharyngotonsillitis in 
patients $12 years of age. The three studies included a 
total of 1322 randomized patients, with 1241 patients in the 
intention-to-treat (ITT) analysis and 1010 patients in the per-
protocol (PP) population. In the pooled analysis of the three 
studies, no significant differences in clinical response were 
found between cefditoren and penicillin V, success rates 
ranging from 89.4% to 95.3%.58 Eradication of S. pyogenes 
was higher with cefditoren at the end of therapy (90.4% 
vs 82.7%; P = 0.002) and at the end of follow-up (84.7% 
vs 76.7%; P = 0.008), although the statistical significance 
set at P , 0.001 was not reached.58
Two additional studies have been recently published for 
cefditoren in the treatment of group A β-hemolytic strepto-
coccal pharyngotonsillitis in children.59,60 Ozaki et al reported 
a study comparing 3 mg/kg cefditoren-pivoxil 3 times daily 
for 5 days versus amoxicillin 10 mg/kg 3 times daily for 
10 days in 258 patients (258 isolates with amoxicillin and 
cefditoren MIC # 0.06 µg/mL).59 Eradication was 100% 
with amoxicillin and 99% with cefditoren pivoxil, with no 
differences in the recurrence rate (15 patients in the amoxicil-
lin arm and 8 patients in the cefditoren arm).59 The second 
study compared the efficacy provided by 9 mg/kg cefditoren 
pivoxil (maximum dose 300 mg/day) 3 times daily for 5 days 
(77 patients) versus 10 days (149 patients) in children with 
history of at least 1 episode of group A β-hemolytic strep-
tococcal pharyngotonsillitis.60 Similar bacteriological failure 
occurred in both arms (9.1% vs 11.4%), but significantly 
higher recurrences were found in the 5 days treatment group 
(9.1% vs 0.7%; P = 0.03).60
Three studies were carried out in adults with acute 
sinusitis during the clinical development of cefditoren, 
using cefuroxime or amoxicillin/clavulanic acid as 
comparators. The three studies included 1819 random-
ized patients: 1726 patients included in the ITT and 1589 
patients in the PP population. In the pooled analysis of 
the three studies, no differences in clinical response were 
found between cefditoren and comparators both at the end 
of therapy (80.2% vs 84.8%) and at the end of follow-up 
(71.2% vs 77.4%).58 An additional study in the treatment 
of bacterial rhinosinusitis in children was recently pub-
lished comparing 4 to 6 mg/kg twice daily (maximum dose 
300 mg/day) versus 80 to 90 mg/kg (on amoxicillin basis) 
amoxicillin/clavulanic acid (maximum dose 800 mg/day) 
twice daily for 14 days.61 Rates of improvement were simi-
lar in both groups (78.8% vs 84.7%) with similar relapse 
rates (9.1% vs 11.1%) or recurrences (3.0% vs 5.6%) of 
sinus symptoms.61
Efficacy clinical studies with 
cefditoren in the treatment 
of community-acquired lower 
respiratory tract infections
Seven studies were carried out in the clinical development of 
cefditoren in the treatment of lower respiratory tract infec-
tions, 4 studies in community-acquired pneumonia (CAP) 
and 3 studies in acute exacerbation of chronic bronchitis 
(AECB). A pooled analysis of data was performed includ-
ing a total of 4159 randomized patients.62 Comparators were 
amoxicillin/clavulanic acid or cefpodoxime in CAP studies, 
and cefuroxime or clarithromycin in AECB studies. Pooled 
data from CAP studies revealed no significant differences in 
response rates between cefditoren and comparators, percent-
ages of responders ranging from 89.2% to 91.8% at the end of 
therapy and from 85.9% to 90.4% at the end of follow-up.62 
Pooled data from the AECB studies resulted in response rates 
ranging from 85.8% to 91.3% at the end of therapy and from 
81.2% to 83.3% at the end of follow-up, without significant 
differences between groups.62
For microbiological assessment, data from CAP and 
AECB studies were pooled. Globally, the bacteriologi-
cally evaluable population consisted of 1910 patients with 
1223 target pathogens isolated prior to treatment initiation, 
  including 406 S. pneumoniae isolates (56 of them nonsus-
ceptible to oral penicillin) and 595 H. influenzae isolates.62 
No significant differences were found in the rate of bacterio-
logical responders for S. pneumoniae, percentages ranging 
from 88.5% to 92.0%. Among penicillin nonsusceptible 
(MIC $ 0.12 µg/mL) S. pneumoniae isolates, all 20 (100%) 
strains in the cefditoren 400 mg group, 84.2% (16 out of 
19) strains in the cefditoren 200 mg group, and 94.1% 
(16 out of 17) strains in the comparator group were eradi-
cated or presumed eradicated.62 Among penicillin-resistant 
(MIC $ 2 µg/mL) isolates, 17 (94.4%) of 18 isolates in both 
cefditoren arms were eradicated or presumed eradicated, 
compared with 10 (90.9%) of 11 in the comparator group.62 
Differences in the rate of responders for H. influenzae were 
also not significant (range 82.7% to 86.6%).62
Bacterial eradication as a goal  
of antibacterial treatment,  
and subsequent clinical efficacy
The correlation between bacterial eradication and clinical 
outcome in respiratory tract infections can be explored in 
streptococcal tonsillopharyngitis as an upper respiratory tract 
infection and AECB as a lower respiratory tract infection, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
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since noninvasive samples for culture are easily collected 
over time. As noted in the previous section, in the pooled 
analysis of studies on tonsillopharyngitis bacteriological 
efficacy was associated with a higher clinical response 
rate.58 Cefditoren (a β-lactamase-resistant cephalosporin) 
showed a tendency of higher bacteriological response for 
S. pyogenes than penicillin (susceptible to β-lactamases 
produced by commensal flora),58 reinforcing the concept of 
“co-pathogenicity” with β-lactamase-producing bacteria. It 
has been hypothesized that β-lactamase from β-lactamase-
producing isolates such as H. influenzae may protect non-
β-lactamase-producing isolates such as S. pyogenes from 
the action of the antibiotic.63,64 In this sense, a previous 
meta-analysis also showed higher bacteriological failures 
with penicillins versus cephalosporins.65 Co-pathogenicity 
was also explored in vitro in a pharmacodynamic simulation 
of free concentrations over 24 hours obtained with 875 mg 
amoxicillin 3 times daily, 875/125 mg amoxicillin/  clavulanic 
acid 3 times daily, and 400 mg cefditoren twice daily using 
individual and mixed inocula (proportions 1:1:1:1) of 1 
S. pyogenes isolate, 1 penicillin-resistant S. pneumoniae, 
1 β-lactamase positive H. influenzae, and 1 BLPACR 
H.   influenzae isolate.66 At 24 hours amoxicillin was able 
to eradicate S. pyogenes in simulations carried out with 
the individual S. pyogenes inoculum but failed to do so in 
simulations with the mixed inocula where S. pyogenes was 
protected by β-lactamases produced by the H. influenzae 
isolates.66 In contrast S.   pyogenes was eradicated by cefdi-
toren, both in individual and mixed simulations where both 
strains of H. influenzae were also eradicated.66
One of the AECB studies included in the pooled analysis 
of lower respiratory tract infections62 exploring the relation-
ship of bacteriological and clinical responses has been indi-
vidually published.67 In this study, including 541 patients, 
inclusion criteria, baseline characteristics of patients (age 
and pre-study smoking history), and the required symptoms 
of exacerbation (Anthonisen I and II) ensured inclusion of 
patients with underlying chronic bronchitis, and increased the 
chance of the bacterial origin of the exacerbation. Improve-
ment/efficacy was more evident in signs linked to the pres-
ence of bacteria, such as rales, ronchi, and the volume and 
purulence of the sputum (which decreased from about 80% 
patients in the pre-treatment visit to about 10% patients at 
day 30) than in signs linked to chronic structural damage 
such as dyspnea which decreased from only about 99% in the 
pre-treatment visit to 75% patients at day 30.67 Globally, per-
pathogen bacterial response related well to clinical success: 
83.5% isolates (out of 164 baseline isolates) from patients 
resulting in clinical response were eradicated or presumably 
eradicated in contrast to only 3% isolates (out of 33 baseline 
isolates) from patients resulting in clinical failure.67
Safety data from clinical trials 
performed during the clinical 
development of cefditoren
Safety data from all the 13 clinical trials carried out during 
the clinical development of cefditoren for the treatment of 
community-acquired respiratory infections were analyzed 
in a pooled analysis.68 Safety population was defined as all 
randomized patients with at least 1 dose intake, and com-
prised 4592 patients for cefditoren.68 Cefditoren exhibited 
an adverse event profile similar to that of previous antibiot-
ics currently used in the treatment of community-acquired 
respiratory tract infections, diarrhea being the most frequent 
adverse event (9.9%) followed by vaginosis (3.9% among 
female population), nausea (3.5%), abdominal pain (1.8%), 
and dyspepsia (1.1%).68
Conclusions
The pharmaceutical industry has decreased its efforts to 
develop new antimicrobials, and the lack of a robust pipeline 
of new compounds has been suggested.69 In this situation, the 
fact that the main ecological effect of antimicrobials is pro-
moting the emergence of resistance70 (a risk associated with 
the imprudent use of available drugs) implies that clinicians 
may have limited options within the current armamentarium. 
Since the use of agents to which pathogens are resistant 
contributes to increased morbidity, mortality, and associated 
expenses,71 the rational use of antibiotics can help to stop 
or minimize the emergence, spread, and diversification of 
antibiotic resistance.
In this context, this article reviews and updates published 
data on cefditoren in the evolving situation of resistance among 
the most prevalent isolates from respiratory tract infections in 
the community. By relating its in vitro activity (from surveil-
lance and in vitro studies including isolates with emerging 
resistant genotypes/phenotypes) to its pharmacokinetics, the 
cefditoren pharmacodynamic activity predicting therapeutic 
efficacy (in humans, animal models, and in vitro simula-
tions) was analyzed prior to reviewing clinical studies and 
the relationship between bacterial eradication and therapeutic 
efficacy. The wide range of studies carried out with cefditoren 
constitutes one of the most extensive and continuous sources 
of data defining the role of a new antibiotic in the community 
and provides information to clinicians (on cefditoren and 
comparators) of relevance to establish empirical therapy.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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The high in vitro activity of cefditoren against the most 
prevalent respiratory isolates in the community, together 
with its pharmacokinetics (allowing a twice daily regimen) 
leading to adequate pharmacodynamic indexes covering all S. 
  pyogenes, H. influenzae, and 94.9% S. pneumoniae isolates, 
makes cefditoren an antibiotic that will play a significant role 
in the treatment of respiratory tract infections in the commu-
nity. In the clinical setting, studies carried out with cefditoren 
showed that treatments with the 400 mg twice daily regimen 
were associated with high rates of bacteriological response, 
even against penicillin nonsusceptible S. pneumoniae, with 
good correlation between bacteriological efficacy/response 
and clinical outcome.
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